Pharmaids Pharmaceuticals Ltd.

As of June 30, 2026, Pharmaids Pharmaceuticals Ltd. carries a market capitalization of 1.37B, placing it among publicly traded companies globally. Its enterprise value stands at 1.37B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Pharmaids Pharmaceuticals Ltd. has 35.27M shares outstanding.

These figures are as of June 30, 2026.

These figures are as of June 30, 2026. The EV/Sales ratio of 5.42 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 1.37B versus a market cap of 1.37B, with the gap driven by net debt and cash on the balance sheet.

These figures are as of June 30, 2026.

These figures cover the twelve months ended June 30, 2026. The company generates approximately 12.67M in revenue per employee across its workforce of 20.00, a quick read on workforce productivity versus industry peers.

Over the twelve months ended June 30, 2026, Pharmaids Pharmaceuticals Ltd. recorded an income tax benefit of -23.32M rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -67.20M and -45.63M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 22, 2026, Pharmaids Pharmaceuticals Ltd.'s stock has declined approximately 41.80% over the past 52 weeks. The 50-day moving average sits at 30.98, while the 200-day moving average is 33.50.

Over the twelve months ended June 30, 2026, Pharmaids Pharmaceuticals Ltd. generated 253.40M in revenue and converted that into -45.63M in net income, yielding earnings per share of -1.24. EBITDA reached -22.11M, while operating income came in at -108.16M.

Over the twelve months ended June 30, 2026, Pharmaids Pharmaceuticals Ltd. posted a gross margin of 39.76, reflecting its pricing power and cost economics. The operating margin of -42.69 and net profit margin of -18.01 provide insight into operational efficiency.